Depression, as many of
us know, is more than just a sad or melancholy mood. It’s more than just having
“the blues.” Sometimes it can be a very debilitating condition that can prevent
people from having productive lives – and in some cases can be a root cause of
suicide and/or fatal drug overdoses.
Depression is often
considered an imbalance of certain chemicals in the brain, and is treated
through various therapies and anti-depressant drugs. However, the very serious
level of depression – the living-in-an-abyss type of depression that was behind
the recent death of actor and comedian Robin Williams (also known as Major
Depressive Disorder, or MDD) – has been very difficult to treat effectively.
There has been a trade-off with some therapies – there are some strong
anti-depressants in the market, but most have side effects that can be
dangerous in their own right – perhaps more so than the depression itself.
VistaGen Therapeutics, Inc. (OTCQB: VSTA) is looking to fill this very
important mental-health gap with its own potential new antidepressant therapy
known as AV-101.
VistaGen’s AV-101 has
gone through the initial Phase 1 clinical development focused on human safety
and the company is now working toward a significant Phase 2 clinical trial of
AV-101 in collaboration with the U.S. National Institutes of Health (NIH). The
NIH previously awarded the company nearly $9 million for its preclinical and
Phase 1 development programs, and the company expects the NIH to sponsor and
conduct the impending Phase 2 efficacy study. VistaGen believes AV-101 is a
potential new generation antidepressant with a novel mechanism of action to
address MDD more rapidly and with fewer and less-severe side effects than other
depression therapies currently being used.
With a successful Phase
2 trial which is expected to be completed by the end of 2015, there could be
some significant momentum for VistaGen Therapeutics in the mental-health
sector, with AV-101 as a novel potential therapy for MDD and other similar mood
disorders that affect millions of Americans. Robin Williams’ sad and tragic
death has brought MDD more prominently into the forefront, and it will be
therapies like AV-101 that will be watched more readily as mental-health
professionals look to encourage more diagnoses of depression and other mood
disorders so they can be treated early and aggressively. This is an environment
for VistaGen Therapeutics to be in the spotlight.
For more information,
visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that
have huge potential to succeed in the short and long-term future. We offer several
ways for investors to find, evaluate, and learn more about investing in these
companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment